Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum

Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum

Review this module by Fadi Ghassan Haddad MD discussing chronicphase chronic myeloid leukemia treatment including optimal therapy selection strategies to optimize treatmentfree remission and overcoming resistance to TKI therapy

  • Provider:Clinical Care Options
  • Activity Link: https://clinicaloptions.com/CE-CME/hematology/chronic-myeloid-leukemia-treatment/22499-47035
  • Start Date: 2024-08-15 05:00:00
  • End Date: 2024-08-15 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
  • Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 99997.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 80000.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.